Holen Sie sich die Stockscreener-App
4.09
16.52%
0.58
Handel nachbörslich:
4.08
-0.010
-0.24%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Altimmune Inc Aktie (ALT) Neueste Nachrichten
Altimmune’s Surprising Stock Surge: What’s Behind It? - StocksToTrade
Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Altimmune shares rally after FDA awards breakthrough status to pemvidutide - MSN
Altimmune (ALT) Surges on FDA Breakthrough Therapy Designation f - GuruFocus
Altimmune stock gains on FDA breakthrough status (ALT:NASDAQ) - Seeking Alpha
FDA grants breakthrough therapy status to Altimmune’s MASH drug By Investing.com - Investing.com Australia
Altimmune jumps after US FDA's 'breakthrough' tag for liver disease drug - TradingView — Track All Markets
Altimmune, Inc. Receives FDA Breakthrough Therapy Designation for Pemvidutide in Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Quiver Quantitative
Altimmune stock soars after FDA grants Breakthrough Therapy status By Investing.com - Investing.com Canada
Altimmune stock soars after FDA grants Breakthrough Therapy status - Investing.com
FDA flags new liver disease drug for faster review after promising early data - Stock Titan
Altimmune Receives FDA’s Breakthrough Therapy Designation For Its Liver Disease Drug - Stocktwits
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% - MSN
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround - The Globe and Mail
Jerome Durso Buys Handful Of Shares In Altimmune - Yahoo Finance
Insider Buying: Altimmune Independent Chairman Bought US$52k Of Shares - simplywall.st
Altimmune, Pure Storage, Globalstar, Cipher Mining, AutoZone Shake-Up - TipRanks
Altimmune announces CEO transition - MSN
Q3 2025 Altimmune Inc Earnings Call Transcript - GuruFocus
Does Altimmune (ALT) have the potential to rally 229.28% as Wall Street analysts expect? - MSN
Insider Buying: John Gill Acquires 12,500 Shares of Altimmune In - GuruFocus
Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen - Seeking Alpha
John Gill Acquires 12,500 Shares of Altimmune (NASDAQ:ALT) Stock - MarketBeat
Altimmune Director John Gill Acquires 12,500 Shares - TradingView — Track All Markets
Altimmune stock soars over 10% premarket on positive mid-stage data for liver disease treatment drug - MSN
Altimmune, Inc. (NASDAQ:ALT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Insider Buying: Jerome Durso Acquires 12,500 Shares of Altimmune Inc (ALT) - GuruFocus
Altimmune (NASDAQ:ALT) Director Jerome Benedict Durso Purchases 12,500 Shares - MarketBeat
Altimmune’s 48-Week MASH Data Still Leave Doubts On Fibrosis Benefit - Citeline News & Insights
Altimmune Director Jerome Benedict Durso Acquires 12,500 Shares - TradingView — Track All Markets
Altimmune: Positives And Negatives Of The IMPACT Data And Recent Updates - Seeking Alpha
Altimmune Slides As Insider Purchases Lose Another US$15k - 富途牛牛
Altimmune Stock Plummets After Disappointing Trial Results - timothysykes.com
Can Altimmune Inc. stock hit analyst price targetsJuly 2025 Reactions & Weekly Watchlist for Hot Stocks - Улправда
How Altimmune Inc. stock compares to market leadersPortfolio Risk Report & Weekly Setup with High ROI Potential - Улправда
Will Altimmune Inc. stock benefit from upcoming earnings reports2025 Price Targets & Community Consensus Trade Signals - Улправда
Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASHSlideshow (NASDAQ:ALT) 2025-12-19 - Seeking Alpha
Why Is Altimmune Stock Up Over 10% Before The Bell? - Stocktwits
Altimmune (ALT) Shares Plunge Following Phase 2b MASH Trial Resu - GuruFocus
ALT Stock Surge: Should You Act? - StocksToTrade
Altimmune's liver disease drug shows benefits in study, but investors remain unimpressed - MSN
Balanced Risk-Reward for Altimmune’s Pemvidutide in a Crowded MASH Landscape Supports Hold Rating - TipRanks
Pemvidutide’s Strong Phase 2b Data and De-Risked Phase 3 Path in MASH Support Altimmune Buy Rating and $12 Target - TipRanks
Altimmune stock tumbles after MASH drug trial data By Investing.com - Investing.com Nigeria
Altimmune stock tumbles after MASH drug trial data - Investing.com
Transcript : Altimmune, Inc.Special Call - marketscreener.com
Altimmune advances in MASH; New China obesity biotech; Ipsen Phase 2 fail - Endpoints News
Altimmune jumps 16% on promising Phase 2b liver disease trial | Tap to know more | Inshorts - Inshorts
Altimmune Stock Soars Over 10% Premarket On Positive Mid-Stage Data For Liver Disease Treatment Drug - Asianet Newsable
Altimmune (ALT) Reports Promising Phase 2b Results for MASH Trea - GuruFocus
Altimmune posts mid-stage trial data for MASH drug (ALT:NASDAQ) - Seeking Alpha
Altimmune releases positive results from MASH dual receptor trial - Traders Union
Altimmune (ALT) Reports Promising Phase 2b Results for Pemviduti - GuruFocus
Altimmune Says Pemvidutide Showed "Significant" Improvements in MASH Patients at 48 Weeks - marketscreener.com
Altimmune reports positive Phase 2b pemvidutide MASH results - TipRanks
2.03%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):